T2DM

Sick Day Medication Guidance: How to Minimize The Harm of Double-Edged Swords?

May 17, 2023 // 0 Comments

Mengyao Tang @tammyyaotang Dr. Mengyao Tang is a research fellow at Massachusetts General Hospital, as well as a board-certified nephrologist who has a particular interest [...]

SGLT2 Inhibitors and AKI: Time to Ditch the Dogma

November 25, 2020 // 1 Comment

Sodium/glucose cotransporter 2 inhibitors (SGLT2i / gliflozins) are a novel class of medications which act by inhibiting the SGLT2 transporter located in the S1 segment of [...]

Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3 CKD

August 15, 2019 // 1 Comment

There has been significant interest in SGLT2 inhibitors (SGLT2i) as novel oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes [...]

AJKD Blog

Official Blog of the American Journal of Kidney Diseases

T2DM

Sick Day Medication Guidance: How to Minimize The Harm of Double-Edged Swords?

SGLT2 Inhibitors and AKI: Time to Ditch the Dogma

Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3 CKD